Athena Athena

X
[{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Initiates Phase 1\/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Franklin Templeton","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Pipeline Therapeutics Completes $80 Million Series C Financing","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Initiates Phase 1 Clinical Trial of PIPE-307","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b\/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics to Present Multiple Posters at SFN 2022 Neuroscience Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics to Present Preclinical Poster on PIPE-791 at the Glial Biology: Functional Interactions Among Glia Neurons, a Gordon Research Conference (GRC)","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$50.0 million","newsHeadline":"Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1 Study of PIPE-791","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pipeline Therapeutics Announces First Subject Dosed with PIPE-791 in Phase 1 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Jeffrey C. Thacker","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Contineum Therapeutics Files for IPO with MS Drug in Phase II","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Pipeline Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The net proceeds will be used in the clinical development of PIPE-307, a small molecule G1 receptor inhibitor. it is being evaluated in the Phase II clinical trial studies for the treatment of Relapsing-remitting Multiple Sclerosis.

            Lead Product(s): PIPE-307

            Therapeutic Area: Neurology Product Name: PIPE-307

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jeffrey C. Thacker

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering March 15, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PIPE-791 is a potent, selective and brain-penetrant small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1), which is investigated for the treatment of MS and other neurological and systemic diseases.

            Lead Product(s): PIPE-791

            Therapeutic Area: Neurology Product Name: PIPE-791

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PIPE-791 is a potent, selective, brain-penetrant small molecule antagonist of the LPA1 receptor that has demonstrated activity in in vitro and in vivo models and was tolerated in IND-enabling studies for Multiple sclerosis.

            Lead Product(s): PIPE-791

            Therapeutic Area: Neurology Product Name: PIPE-791

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 08, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement leverages Pipeline’s expertise in precision neuroregeneration and Janssen’s development experience across nervous system disorders for the investigational compound, PIPE-307, an oral, highly selective antagonist of the muscarinic M1 receptor.

            Lead Product(s): PIPE-307

            Therapeutic Area: Neurology Product Name: PIPE-307

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

            Deal Size: $1,100.0 million Upfront Cash: $50.0 million

            Deal Type: Licensing Agreement April 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PIPE-791 is a preclinical program and focuses on antagonism of the LPA1 receptor. LPA is a naturally occurring inflammatory lipid and its dysregulation has been implicated in inflammatory diseases, such as MS.

            Lead Product(s): PIPE-791

            Therapeutic Area: Neurology Product Name: PIPE-791

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PIPE 791, a lysophosphatidic acid (LPA1) receptor antagonist is being developed by Pipeline Therapeutics for the treatment of demyelinating disorders.

            Lead Product(s): PIPE-791

            Therapeutic Area: Neurology Product Name: PIPE-791

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PIPE-307, highly selective antagonist of M1 muscarinic receptor commencing clinical studies in MS patients. Results from PET study demonstrate that doses tested in Phase 1 study achieve a level of uptake in human brain.

            Lead Product(s): PIPE-307

            Therapeutic Area: Neurology Product Name: PIPE-307

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PIPE-307, as a first-in-class myelin restoration therapeutic, demonstrated linear pharmacokinetic (PK) data consistent with preclinical modeling and was generally well tolerated across all dose cohorts.

            Lead Product(s): PIPE-307

            Therapeutic Area: Neurology Product Name: PIPE-307

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of PIPE-307 will primarily assess the safety and tolerability profile of PIPE-307, as well as measure the effect of PIPE-307 on pharmacokinetics.

            Lead Product(s): PIPE-307

            Therapeutic Area: Immunology Product Name: PIPE-307

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Pipeline Therapeutics plans to use the proceeds to advance its development candidates PIPE-505, in patients with sensorineural hearing loss, and PIPE-307, in patients with multiple sclerosis.

            Lead Product(s): PIPE-505

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: PIPE-505

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Franklin Templeton

            Deal Size: $80.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing February 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY